Last reviewed · How we verify

Shilpa Grover, MD, MPH — Portfolio Competitive Intelligence Brief

Shilpa Grover, MD, MPH pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Prednisone Taper Prednisone Taper marketed Corticosteroid (glucocorticoid) Glucocorticoid receptor (GR) Immunology, Rheumatology, Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Astellas Pharma Inc · 1 shared drug class
  3. Benazir Bhutto Hospital, Rawalpindi · 1 shared drug class
  4. Berinstein, Jeffrey · 1 shared drug class
  5. Celgene · 1 shared drug class
  6. Children's Hospital of Philadelphia · 1 shared drug class
  7. Chong Kun Dang Pharmaceutical · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shilpa Grover, MD, MPH:

Cite this brief

Drug Landscape (2026). Shilpa Grover, MD, MPH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shilpa-grover-md-mph. Accessed 2026-05-16.

Related